



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Feige et al.

Serial No.: 10/666,696

Group Art Unit No.: 1642

Filed: September 19, 2003

Examiner: S. Huff

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527H

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111

Phone: (805) 447-2688

Date: December 18, 2003

Please send all future correspondence to:  
US Patent Operations/ [TJG]  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EV352488785US


Date of Deposit:

December 18, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

J. L. ST. ANDREW  
Printed Name

J. L. St. Andrew  
Signature



Modified Form PTO-1449

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

A-527H

Serial No.

10/666.696

Applicant

Feige et al.

Filing Date

September 19, 2003

Group

1642

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,521,073	05/28/96	Davis et al.			
	A2	5,643,755	07/01/97	Davis et al.			
	A3	5,650,490	07/22/97	Davis et al.			
	A4	5,814,464	09/29/98	Davis et al.			
	A5	5,879,672	03/09/99	Davis et al.			
	A6	5,955,291	09/21/99	Alitalo et al.			
	A7	5,972,338	10/26/99	Godowski et al.			
	A8	6,030,831	02/29/00	Godowski et al.			
	A9	6,166,185	12/26/00	Davis et al.			
	A10	6,323,323	11/27/01	Sledziewski et al.			


**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
✓	B1	WO 95/13387	05/18/95	PCT				
✓	B2	WO 95/21866	08/17/95	PCT				
✓	B3	WO 98/05779	02/12/98	PCT				
✓	B4	WO 98/18914	05/07/98	PCT				
✓	B5	WO 99/43801	09/02/99	PCT				
✓	B6	WO 00/57901	10/05/00	PCT				
✓	B7	WO 00/06195	02/10/00	PCT				
✓	B8	WO 00/75323	12/14/00	PCT				
✓	B9	WO 00/77037	12/21/00	PCT				
✓	B10	WO 01/62891	8/30/01	PCT				

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## Atty. Docket No.

A-527H

Serial No.

10/666.696

Applicant

Feige et al.

<b>Filing Date</b>	03/20/2017
--------------------	------------

September 19, 2003

Group
-------

1642

(Use several sheets if necessary)

✓

C1 Connell et al. (2001), "Patent Focus on Cancer Chemotherapeutics. III Angiogenesis Agents: October 2000 - March 2001," *Ashley Publications Ltd. ISSN 1354-3776*, pp. 1171-1203.

—

C2 Coxon et al. (2002), "Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis," *Arthritis Rheum.* 46:2604-2612.



C3	Feige et al. (2000), "Anti-interleukin-1 and anti-tumor necrosis factor- $\alpha$ synergistically inhibit adjuvant arthritis in Lewis rats," <i>Cell Mol. Life Sci.</i> 57:1457-1470.
----	---

2

C4	Peacock et al. (1992), "Angiogenesis inhibition suppresses collagen arthritis," <i>J. Exp. Med.</i> 175:1135-1138.
----	--

C5	Peacock et al. (1995), "A novel angiogenesis inhibitor suppresses rat adjuvant arthritis," <i>Cell Immunol.</i> 160:178-184.
----	--

—

C6	Walsh et al. (2001), "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153.
----	---

**EXAMINER:**

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.